CHECKOUT
Step 1/4
Research »
LNTH
Lantheus Holdings
  • Vol:
 

Lantheus Holdings (LNTH)

 
.

Lantheus Holdings (LNTH) - Develops diagnostic medical imaging agents and products for the diagnosis of cardiovascular/other diseases.

 GROUP LEADERSHIP
Medical-Products Group
LNTH
is ranked
#17
17th in group
DXCM
is ranked
#1
1st in group
More analysis for DXCM:
 IBD RATINGS FOR LNTH
  • Checklist
  • Rating

Take a Free Trial to see all ratings

LNTH NEWS
  • LNTH NEWS FROM IBD
  • LNTH NEWS - IBD PARTNERS
IBD

Lantheus Holdings Clears Technical Benchmark, Hitting 80-Plus RS Rating

Investor's Business Daily 12/13/2023 03:00 AM ET

DexCom Stock Earns Healthy Relative Strength Rating Upgrade

Investor's Business Daily 12/05/2023 02:03 PM ET

Stocks With Rising Relative Price Strength: Lantheus Holdings

Investor's Business Daily 12/05/2023 03:00 AM ET

IBD Rating Upgrades: Lantheus Holdings Shows Improved Technical Strength

Investor's Business Daily 11/17/2023 03:00 AM ET

Boston Scientific Stock Sees IBD RS Rating Improve To 74

Investor's Business Daily 10/16/2023 02:41 PM ET

View All »

IBD Partners
No News Available.
 STOCK/COMPANY DATA FOR LNTH
    Stock Data
  • Today's Range
  • 61.63  -  65.26
  • 52-Week Range
  • 50.20  -  100.85
  • Price % Chg. YTD
  • 0.53%
  • Price % Chg. Last 4 Weeks
  • 0.14%
  • 50-Day Avg. Volume
  • 866,200
  • Shares Outstanding
  • 68.6 Mil
  • Float
  • 66.5 Mil
  • IPO Date
  • 06/25/2015
  • Investment Bank
  • Credit Suisse
  • % Mgmt Owns
  • 2.1%
  • PE Ratio
  • 10
  • Dividend Yield
  • 0
  • Alpha
  • -0.14
  • Beta
  • 0.74
    Company Fundamentals
  • EPS Due Date
  • 4/26/2024
  • EPS % Chg (Last Qtr)
  • 28%
  • 3 Year EPS Growth Rate
  • 236%
  • EPS Est % Chg (Current Yr)
  • 6%
  • Annual ROE
  • 69.3%
  • Sales % Chg (Last Qtr)
  • 35%
  • 3-Year Sales Growth Rate
  • 68%
  • Debt %
  • 69%
  • Market Cap
  • $4.3 B $4 Bil
  • Annual Pre -Tax Margin
  • 45.7%
  • Sector
  • medical
  • Industry Group
  • Medical-Products
  • Industry Group Rank
  • 55